Loading...
XSHE
002422
Market cap7.62bUSD
Dec 05, Last price  
33.73CNY
1D
-1.09%
1Q
-16.41%
Jan 2017
109.24%
IPO
-5.52%
Name

Sichuan Kelun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002422 chart
P/E
18.36
P/S
2.47
EPS
1.84
Div Yield, %
2.37%
Shrs. gr., 5y
2.12%
Rev. gr., 5y
4.34%
Revenues
21.81b
+1.67%
2,029,326,5502,621,391,2863,245,985,3454,026,399,9585,147,848,7585,885,278,6176,831,281,9818,023,421,2897,763,339,9828,565,943,41511,434,948,84116,351,790,23917,636,267,04416,464,201,27717,277,407,53318,912,653,46321,453,929,23721,812,414,489
Net income
2.94b
+19.53%
216,288,383309,887,206427,851,436661,229,249966,126,0951,087,515,7481,079,521,5861,001,902,613645,271,323584,638,829748,544,1871,212,944,249937,855,128829,386,336868,116,5331,705,324,0672,456,112,0452,935,892,103
CFO
4.49b
-15.82%
168,423,194221,075,877250,688,633149,292,039342,931,058402,771,4671,050,373,8451,218,735,9381,239,429,4361,725,407,4151,102,520,8282,953,506,9672,216,737,6392,219,381,5192,847,118,4283,127,457,0905,337,068,9314,492,861,844
Dividend
May 29, 20240.8 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers IV solutions; injectable powder and small volume parenteral; oral preparation; intermediates and APIs; and peritoneal dialysis solutions. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT